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Abstract
Background
Access to adequate treatment for opioid use disorder (OUD) has been a high priority among
American policymakers. Elucidation of the sociodemographic and institutional differences
associated with the use, or lack thereof, of opioid agonist therapy (OAT) provides greater
clarity on who receives OAT. Timely access to care is a further consideration and bears
scrutiny as well.
Methods
We draw upon data from the Treatment Episode Data Set—Admissions (TEDS-A) to ana-
lyse the relationship between sociodemographic and institutional characteristics and the
receipt of opioid agonist treatments and time waiting to enter treatment.
Results
Estimates from logistic regression models highlight certain groups which show lower odds
of receipt of OAT, including those in precarious housing arrangements, those unemployed
or not otherwise in the labor force, and those referred by drug abuse care providers, educa-
tional institutions, employers, and the criminal justice system. Groups which showed
higher odds of waiting over a week to enter treatment included those who were separated,
divorced, or widowed, those working part-time, and those referred by drug abuse care pro-
viders, employers, and the criminal justice system.
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Conclusion
Given the efficacy of OAT and the adverse outcomes associated with long waiting times,
coordinated effort is needed to understand why these differences persist and how they may
be addressed through appropriate policy responses.
Introduction
In 2010 the global burden of disease attributable to opioid dependence was 9.2 million disabil-
ity-adjusted life years (DALYs) with 15.5 million individuals suffering from opioid depen-
dence and a significantly high burden of premature mortality affecting North America and
Eastern Europe [1]. In 2015, over 33,000 deaths from overdoses were recorded in the United
States, nearly equal to the number of deaths from traffic accidents for the same period, with
deaths from heroin alone exceeding those from homicides involving firearms [2]. The opioid
epidemic in the United States has been one of the most pressing public health challenges iden-
tified by the United States Centers for Disease Control and Prevention (CDC) [2], involving
both heroin use, proved to be exacerbated by socioeconomic vulnerability [3], as well as ease of
accessibility and over prescription of synthetic opioids such as oxycodone and fentanyl, respec-
tively, which appear to fuel the increasing toxicity and mortality of these substances [4]. The
effects of this increasing prevalence has been an upsurge in opioid-related overdose deaths that
have tripled between 1999 and 2014, with 60.9% of drug-related deaths involving an opioid
[5]. Moreover, use disorders involving prescription and synthetic opioids has steadily
increased; from 1997 to 2011, the number of individuals seeking treatment for opioid addic-
tion increased by 900% [2]. Despite the urgent need for additional capacity and health system
responsiveness for opioid use disorder (OUD) treatment, including the need for qualified care
providers and available space in substance abuse treatment facilities, individuals with OUDs
continue to face barriers to evidence-based treatment such as psychotherapy and opioid ago-
nist treatments (OATs) which are established best practice [6, 7]. One national study in 2013
found, for instance, that lifetime cumulative probability of treatment-seeking among individu-
als with opioid addiction was only 42% with a median delay of 3.83 years from onset of
disorder to first treatment [8]. A more recent study has also highlighted racial and ethnic dif-
ferences in OAT for OUD which signal a greater need for focus to understand and overcome
potential barriers to treatment to promote health equity [9]. These findings, in conjunction
with research that show that opiate-dependent patients waiting for treatment are at heightened
risk for mortality [10], indicate a need for greater scrutiny of barriers to treatment. In addition
to barriers to treatment, the type and mode of treatment received by individuals with OUD
has also been at the centre of the access barriers debate [11, 12]. OATs, such as methadone
[13], are cost-effective, evidence-based treatments for OUD, especially compared against absti-
nence-based treatments [13, 14]. Nevertheless, OATs have historically been subject to height-
ened scrutiny in the United States; for example, the use of methadone is strictly regulated by
the Drug Addiction Treatment Act (DATA) of 2000 and limited only to certified Opioid
Treatment Programs (OTPs) [15]. Given the stringent regulatory oversight of OATs for the
treatment of OUD amid the opioid crisis, the accessibility of OATs and the capacity to treat
OUD has come under heightened scrutiny [16] with some calling for increased access to
buprenorphine in the outpatient setting [17]. Moreover, given the urgency of non-medical use
of prescription opioids (NMUPO), some attention has also been devoted to the timely receipt
of care for OUD [18].
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Our aim was to examine and identify patients with OUD in specialty addiction programs at
risk of not receiving OAT as well as delayed entry to treatment based on: sociodemographic,
and institutional characteristics. In this study, we draw upon the Treatment Episode Dataset
(TEDS), an administrative dataset of annual admissions to substance abuse treatment facilities
to analyse the differential use of OAT among admitted patients by patient characteristics as
well as factors underlying time to enter treatment.
Material and methods
Data source
We used data from the Treatment Episode Data Set—Admissions (TEDS-A), a national
administrative, fully anonymized dataset coordinated and maintained by the Center for Behav-
ioral Health Statistics and Quality at the Substance Abuse and Mental Health Service Adminis-
tration (SAMHSA), for admissions from 2014–17 [19]. TEDS-A captures information at
intake on all publicly-funded admissions to public and private substance abuse treatment
facilities in all 50 States, the District of Columbia, and Puerto Rico, as well as some privately-
funded admissions to facilities which receive public funding, depending on whether State reg-
ulations require this information or not [19]. The unit of analysis in TEDS-A is admission,
not an individual; consequently, an individual may be represented as multiple admissions in
TEDS-A [19]. Nevertheless, the TEDS-A data file excludes admissions known to be transfers
from one level of care to another within a single treatment episode for the same provider [19].
Collected information includes: sociodemographic characteristics of admitted patients, such as
sex, age, and primary source of income, and their substance use behaviours, such as types of
substances used, institutional information pertaining to the admission, and indicators of beha-
vioural health of admitted patients [19].
Our analyses included all first-time admissions for opioid treatment where at least one of:
heroin, non-prescription methadone, or other opiates was reported as the primary, secondary,
or tertiary substance of abuse at time of admission (where TEDS-A only captures up to three
substances of abuse at time of admission). Given our interest in the long-term treatment of
OUDs with OATs vis-à-vis acute detoxification treatments, we excluded patients who were
admitted only for detoxification treatment. As our outcome variables of interest were whether
or not an admitted patient received opioid agonist therapy and time waiting to enter treat-
ment, we excluded states which reported no patients receiving opioid agonist therapy (Geor-
gia, Kansas, Montana, North Dakota, Oklahoma, Virginia, and West Virginia) or states
missing data regarding time waiting to enter treatment (Connecticut, Georgia, Kentucky, Min-
nesota, New York, North Carolina, Oklahoma, Oregon, Rhode Island, Vermont, Virginia,
Washington, and West Virginia) for each analysis, respectively, as these were likely to repre-
sent reporting errors or non-response for optional modules of TEDS-A. On This approach has
been adopted elsewhere [20].
Study variables
Our primary outcome variables were whether an admitted patient received OAT, coded as a
dichotomous variable by SAMHSA; and days waiting to enter treatment, coded as an ordinal
categorical variable by SAMHSA (i.e. no wait, within one week, within two weeks, within one
month, and more than one month). For our analysis of time waiting to enter treatment, we
further dichotomized time waiting to enter treatment as either: within one week or greater
than one week. This interval was selected given the clinical importance of timely OAT initia-
tion for patients experiencing physiological dependence arising from OUD [21].
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Independent variables were categorized as sociodemographic or institutional. Demographic
independent variables included age, sex, ethnicity, marital status, living arrangement, and vet-
eran status. Socioeconomic variables included years of education, employment status, primary
source of income, and health insurer. Institutional characteristics included service setting at
time of admission and primary source of referral. These independent variables have been well-
characterized in TEDS-A and used extensively in other comparable analyses [22–27].
In addition to variables already provided in TEDS-A, namely sociodemographic character-
istics of admitted patients and institutional characteristics pertaining to admission, we coded
for a dichotomous variable to indicate the reported use of alcohol or benzodiazepines on
admission, both of which contraindicate the use of OAT for OUD [28] and could confound
our analysis of receipt of OAT.
Statistical analysis
All statistical analyses were performed in Stata 14 [29]. For our analyses of OAT, a dichotomous
outcome variable indicating whether an admitted patient received OAT, we conducted multiple
maximum-likelihood logit regressions to simultaneously model how sociodemographic charac-
teristics of admitted patients and institutional characteristics pertaining to admission were
related to OAT. For our analyses of days waiting to enter treatment, a categorical outcome vari-
able, we conducted multiple maximum-likelihood logistic regressions to simultaneously model
how our predictor variables were related to a wait time of over one week to enter treatment.
Results
Descriptive sample characteristics are presented in Tables 1 and 2. Of the 6,559,735 admissions
included in the 2014–17 TEDS-A dataset, 479,322 first-time admissions for OUD treatment
were included in our analysis. We note that just over one-third of admitted patients in our
sample received OAT and nearly three-quarters of admitted patients were treated with no
reported wait time.
Use of opioid agonist therapy
The unadjusted and adjusted results of logistic regression of patient and institutional charac-
teristics on receipt of OAT are shown in Table 3.
Sociodemographic characteristics. We found that the odds of receipt of OAT were
higher in all age groups relative to the reference group (aged 18–20) with the highest odds of
receipt of OAT reported by those in age groups 45–49, 50–54, and 55+. Women showed very
slightly higher odds of receipt of OAT compared to men. Native Americans showed higher
odds of receipt of OAT compared to White Americans while those reporting Other as ethnicity
showed lower odds. Compared to those reporting never having married, all other groups
showed lower odds of receipt of OAT. Those reporting a dependent or homeless living situa-
tion showed lower odds of receipt of OAT compared to those who reported an independent
living situation. There was no statistically significant difference in the odds of receipt of OAT
between veterans and non-veterans. Compared to those working full-time, those who were
unemployed or otherwise not in the labor force exhibited lower odds of receipt of OAT. Those
insured by either Medicaid or Medicare showed higher odds of receipt of OAT.
Institutional characteristics. Those admitted to short-term care facilities or an ambula-
tory care setting showed statistically significantly higher odds of receipt of OAT compared to
those admitted to the hospital setting. All primary sources of referral showed lower odds of
receipt of OAT compared with the reference group of individually referred (including self-
referred) patients.
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Table 1. Characteristics of admitted patients either receiving or not receiving opioid agonist therapy for opioid use disorder, 2014–17.
Characteristic Medication-Assisted Opioid Therapy
No Yes Total
No. % No. %
Age
18–20 15,850 82.1 3,446 17.9 19,296
21–24 49,224 75 16,399 25 65,623
25–29 76,169 69.2 33,939 30.8 110,108
30–34 56,587 65.4 29,960 34.6 86,547
35–39 35,327 62.5 21,199 37.5 56,526
40–44 20,810 58.1 14,998 41.9 35,808
45–49 16,546 51 15,915 49 32,461
50–54 12,848 45.9 15,165 54.1 28,013
55+ 13,449 41.6 18,881 58.4 32,330
Total 296,810 63.6 169,902 36.4 466,712
Sex
Male 171,350 64.1 95,763 35.9 267,113
Female 125,407 62.9 74,121 37.1 199,528
Total 296,757 63.6 169,884 36.4 466,641
Ethnicity
White 232,348 67.1 113,809 32.9 346,157
Black or African American 31,093 51.3 29,525 48.7 60,618
Asian or Pacific Islander 2,545 59.1 1,761 40.9 4,306
Native American 5,408 72.7 2,032 27.3 7,440
Other 19,613 57.1 14,753 42.9 34,366
Total 291,007 64.3 161,880 35.7 452,887
Marital Status
Never Married 161,768 66.2 82,587 33.8 244,355
Married 35,931 64.1 20,163 35.9 56,094
Separated 14,626 72.5 5,556 27.5 20,182
Divorced or Widowed 29,048 68.3 13,510 31.7 42,558
Total 241,373 66.5 121,816 33.5 363,189
Living Arrangement
Independent 202,019 60.7 130,699 39.3 332,718
Dependent 55,161 73.7 19,643 26.3 74,804
Homeless 29,199 74.6 9,961 25.4 39,160
Total 286,379 64.1 160,303 35.9 446,682
Veteran Status
No 264,993 63.5 152,523 36.5 417,516
Yes 5,934 63.4 3,430 36.6 9,364
Total 270,927 63.5 155,953 36.5 426,880
Education
<8 Years 13,790 64.6 7,567 35.4 21,357
9–11 Years 60,295 63.9 34,096 36.1 94,391
12 Years 140,093 64 78,825 36 218,918
13–15 Years 57,293 71.6 22,716 28.4 80,009
16+ Years 15,655 62.8 9,285 37.2 24,940
Total 287,126 65.3 152,489 34.7 439,615
Employment Status
(Continued)
Differences in opioid agonist treatment and time to enter treatment for opioid use disorder, 2014-17
PLOS ONE | https://doi.org/10.1371/journal.pone.0226349 December 12, 2019 5 / 16
Days waiting to enter treatment
The unadjusted and adjusted results of logistic regression of patient and institutional charac-
teristics on time waiting to enter treatment (i.e. one week or less compared to more than one
week) are shown in Table 4.
Table 1. (Continued)
Characteristic Medication-Assisted Opioid Therapy
No Yes Total
No. % No. %
Full-Time 43,621 61.6 27,175 38.4 70,796
Part-Time 21,843 62.1 13,352 37.9 35,195
Unemployed 132,192 69.8 57,303 30.2 189,495
Not in Labor Force 94,569 61 60,381 39 154,950
Total 292,225 64.9 158,211 35.1 450,436
Source Of Income/Support
Wages/Salary 46,554 62.1 28,460 37.9 75,014
Public Assistance 12,312 45.9 14,490 54.1 26,802
Retirement/Pension or Disability 9,815 46.3 11,387 53.7 21,202
Other 27,174 60.9 17,427 39.1 44,601
None 68,862 79.9 17,310 20.1 86,172
Total 164,717 64.9 89,074 35.1 253,791
Health Insurance
Private 11,591 74.8 3,896 25.2 15,487
Medicaid 53,938 45.6 64,462 54.4 118,400
Medicare or Other 12,074 68.4 5,588 31.6 17,662
Uninsured 53,543 82.9 11,060 17.1 64,603
Total 131,146 60.7 85,006 39.3 216,152
Service Setting At Admission
Hospital 1,735 93.1 129 6.9 1,864
Short-Term 51,556 92.6 4,105 7.4 55,661
Long-Term 30,844 93 2,329 7 33,173
Ambulatory, Intensive Outpatient 54,297 88 7,387 12 61,684
Ambulatory, Non-Intensive Outpatient 158,361 50.4 155,865 49.6 314,226
Total 296,793 63.6 169,815 36.4 466,608
Principal Source Of Referral
Individual (including Self-Referral) 110,118 45.8 130,248 54.2 240,366
Alcohol/Drug Abuse Care Provider 22,933 72.4 8,750 27.6 31,683
Other Health Care Provider 24,310 76.4 7,513 23.6 31,823
Educational Institution 209 86.7 32 13.3 241
Employer 1,167 92.2 99 7.8 1,266
Other Community Referral 34,836 68.7 15,864 31.3 50,700
Court/Criminal Justice Referral/DUI 96,218 93.8 6,356 6.2 102,574
Total 289,791 63.2 168,862 36.8 458,653
Alcohol or Benzodiazepines Reported at Admission
No 214,354 58.4 152,996 41.6 367,350
Yes 82,456 83 16,906 17 99,362
Total 296,810 63.6 169,902 36.4 466,712
https://doi.org/10.1371/journal.pone.0226349.t001
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Table 2. Characteristics of admitted patients by days waiting to enter treatment for opioid use disorder, 2014–17.
Characteristic Days Waiting to Enter Treatment
No wait Within one week Within two weeks Within one
month
More than one
month
Total
No. % No. % No. % No. % No. %
Age
18–20 8,236 68.2 2,551 21.1 627 5.2 482 4 172 1.4 12,068
21–24 29,803 70.7 8,067 19.1 2,119 5 1,631 3.9 516 1.2 42,136
25–29 53,751 72.9 12,964 17.6 3,422 4.6 2,589 3.5 1,009 1.4 73,735
30–34 42,989 73.7 10,138 17.4 2,478 4.2 1,966 3.4 736 1.3 58,307
35–39 28,480 74.5 6,355 16.6 1,655 4.3 1,247 3.3 510 1.3 38,247
40–44 18,507 75.7 4,103 16.8 893 3.7 681 2.8 262 1.1 24,446
45–49 18,219 78.1 3,509 15 815 3.5 593 2.5 196 0.8 23,332
50–54 16,535 79.8 3,000 14.5 586 2.8 461 2.2 150 0.7 20,732
55+ 20,012 81.9 3,097 12.7 637 2.6 495 2 193 0.8 24,434
Total 236,532 74.5 53,784 16.9 13,232 4.2 10,145 3.2 3,744 1.2 317,437
Sex
Male 134,703 74.4 30,936 17.1 7,460 4.1 5,838 3.2 2,179 1.2 181,116
Female 101,799 74.7 22,840 16.8 5,767 4.2 4,304 3.2 1,564 1.1 136,274
Total 236,502 74.5 53,776 16.9 13,227 4.2 10,142 3.2 3,743 1.2 317,390
Race
White 166,028 72.6 41,247 18 10,417 4.6 8,071 3.5 2,978 1.3 228,741
Black or African American 38,506 79.7 7,103 14.7 1,461 3 986 2 265 0.5 48,321
Asian or Pacific Islander 2,445 73.9 603 18.2 107 3.2 114 3.4 38 1.1 3,307
Native American 2,508 74.6 507 15.1 148 4.4 130 3.9 70 2.1 3,363
Other 16,070 75.7 3,225 15.2 902 4.2 697 3.3 333 1.6 21,227
Total 225,557 74 52,685 17.3 13,035 4.3 9,998 3.3 3,684 1.2 304,959
Marital Status
Never Married 115,434 71.2 32,037 19.8 7,498 4.6 5,479 3.4 1,729 1.1 162,177
Married 22,734 70.5 6,420 19.9 1,563 4.8 1,131 3.5 379 1.2 32,227
Separated 8,620 70 2,361 19.2 658 5.3 504 4.1 169 1.4 12,312
Divorced or Widowed 18,364 69.3 5,399 20.4 1,383 5.2 1,002 3.8 338 1.3 26,486
Total 165,152 70.8 46,217 19.8 11,102 4.8 8,116 3.5 2,615 1.1 233,202
Living Arrangement
Independent 158,464 73.8 38,170 17.8 9,192 4.3 6,645 3.1 2,336 1.1 214,807
Dependent 44,128 74.8 9,312 15.8 2,445 4.1 2,193 3.7 890 1.5 58,968
Homeless 20,257 71.5 5,114 18.1 1,393 4.9 1,121 4 446 1.6 28,331
Total 222,849 73.8 52,596 17.4 13,030 4.3 9,959 3.3 3,672 1.2 302,106
Veteran Status
No 213,260 73.8 50,307 17.4 12,538 4.3 9,446 3.3 3,421 1.2 288,972
Yes 4,869 71.6 1,317 19.4 278 4.1 253 3.7 88 1.3 6,805
Total 218,129 73.7 51,624 17.5 12,816 4.3 9,699 3.3 3,509 1.2 295,777
Education
<8 Years 9,325 73.8 2,256 17.9 496 3.9 409 3.2 146 1.2 12,632
9–11 Years 48,243 74.2 10,996 16.9 2,730 4.2 2,249 3.5 805 1.2 65,023
12 Years 112,701 73.5 27,332 17.8 6,603 4.3 4,925 3.2 1,829 1.2 153,390
13–15 Years 32,722 69.3 9,233 19.6 2,546 5.4 1,942 4.1 775 1.6 47,218
16+ Years 12,214 76.3 2,536 15.8 660 4.1 459 2.9 140 0.9 16,009
Total 215,205 73.1 52,353 17.8 13,035 4.4 9,984 3.4 3,695 1.3 294,272
(Continued)
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Sociodemographic characteristics. Only those aged 21–24 showed higher odds of waiting
over a week to enter treatment compared to the reference group of those aged 18–20. No statis-
tically significant difference in the odds of waiting over a week were found between men and
women. Black or African Americans showed lower odds of waiting over a week to enter
Table 2. (Continued)
Characteristic Days Waiting to Enter Treatment
No wait Within one week Within two weeks Within one
month
More than one
month
Total
No. % No. % No. % No. % No. %
Employment Status
Full-Time 31,458 72.4 8,137 18.7 1,964 4.5 1,375 3.2 518 1.2 43,452
Part-Time 16,544 72.3 4,074 17.8 1,174 5.1 788 3.4 297 1.3 22,877
Unemployed 89,931 72 22,929 18.4 5,956 4.8 4,471 3.6 1,588 1.3 124,875
Not in Labor Force 85,056 76.2 17,899 16 4,017 3.6 3,378 3 1,272 1.1 111,622
Total 222,989 73.6 53,039 17.5 13,111 4.3 10,012 3.3 3,675 1.2 302,826
Source Of Income/Support
Wages/Salary 38,861 71.4 10,421 19.1 2,612 4.8 1,894 3.5 647 1.2 54,435
Public Assistance 15,807 77 3,352 16.3 666 3.2 529 2.6 167 0.8 20,521
Retirement/Pension or Disability 13,882 76.7 2,996 16.6 577 3.2 475 2.6 167 0.9 18,097
Other 17,382 74.1 4,498 19.2 820 3.5 582 2.5 164 0.7 23,446
None 42,976 66.3 14,550 22.5 3,320 5.1 2,930 4.5 1,013 1.6 64,789
Total 128,908 71.1 35,817 19.8 7,995 4.4 6,410 3.5 2,158 1.2 181,288
Health Insurance
Private 8,586 61.1 4,105 29.2 735 5.2 485 3.5 140 1 14,051
Medicaid 85,714 80.1 15,646 14.6 2,804 2.6 2,234 2.1 632 0.6 107,030
Medicare or Other 10,251 73.8 2,445 17.6 552 4 466 3.4 167 1.2 13,881
Uninsured 40,396 69.2 12,134 20.8 2,861 4.9 2,313 4 708 1.2 58,412
Total 144,947 75 34,330 17.8 6,952 3.6 5,498 2.8 1,647 0.9 193,374
Service Setting At Admission
Hospital 85 26.6 122 38.2 42 13.2 50 15.7 20 6.3 319
Short-Term 22,173 64.7 7,710 22.5 2,234 6.5 1,717 5 462 1.3 34,296
Long-Term 14,419 59 5,772 23.6 1,634 6.7 1,760 7.2 856 3.5 24,441
Ambulatory, Intensive Outpatient 33,292 68.2 11,170 22.9 2,307 4.7 1,583 3.2 433 0.9 48,785
Ambulatory, Non-Intensive Outpatient 166,537 79.5 29,007 13.8 7,014 3.3 5,035 2.4 1,973 0.9 209,566
Total 236,506 74.5 53,781 16.9 13,231 4.2 10,145 3.2 3,744 1.2 317,407
Principal Source Of Referral
Individual (including Self-Referral) 132,257 78.3 25,967 15.4 5,390 3.2 3,830 2.3 1,387 0.8 168,831
Alcohol/Drug Abuse Care Provider 14,981 65.5 5,328 23.3 1,411 6.2 977 4.3 179 0.8 22,876
Other Health Care Provider 11,028 70 3,248 20.6 729 4.6 532 3.4 209 1.3 15,746
Educational Institution 87 68.5 26 20.5 7 5.5 4 3.1 3 2.4 127
Employer 266 65.8 94 23.3 27 6.7 17 4.2 0 0 404
Other Community Referral 26,036 75.1 5,837 16.8 1,464 4.2 1,046 3 301 0.9 34,684
Court/Criminal Justice Referral/DUI 47,123 68.3 12,744 18.5 4,001 5.8 3,570 5.2 1,541 2.2 68,979
Total 231,778 74.4 53,244 17.1 13,029 4.2 9,976 3.2 3,620 1.2 311,647
Alcohol or Benzodiazepines Reported at Admission
Substance Not Reported 199,639 76.2 41,930 16 9,856 3.8 7,641 2.9 2,861 1.1 261,927
Substance Reported 36,893 66.5 11,854 21.4 3,376 6.1 2,504 4.5 883 1.6 55,510
Total 236,532 74.5 53,784 16.9 13,232 4.2 10,145 3.2 3,744 1.2 317,437
https://doi.org/10.1371/journal.pone.0226349.t002
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Table 3. Logistic regression estimates for receipt of opioid agonist therapy for opioid use disorder among admitted patients, 2014–17.
Characteristic Unadjusted Adjusted�
OR 95% CI AOR 95% CI
Age
18–20 1 1
21–24 1.532 (1.471–1.596) 1.527 (1.377–1.693)
25–29 2.049 (1.971–2.131) 1.780 (1.612–1.966)
30–34 2.435 (2.341–2.533) 2.083 (1.884–2.304)
35–39 2.760 (2.650–2.874) 2.365 (2.130–2.625)
40–44 3.315 (3.177–3.459) 2.706 (2.426–3.018)
45–49 4.424 (4.239–4.618) 3.023 (2.706–3.378)
50–54 5.429 (5.197–5.672) 3.024 (2.698–3.390)
55+ 6.457 (6.186–6.741) 3.444 (3.068–3.865)
Female 1.058 (1.045–1.070) 1.113 (1.076–1.151)
Ethnicity
White 1 1
Black or African American 1.939 (1.905–1.973) 0.987 (0.941–1.035)
Asian or Pacific Islander 1.413 (1.329–1.502) 0.882 (0.733–1.060)
Native American 0.767 (0.729–0.808) 1.355 (1.122–1.637)
Other 1.536 (1.501–1.571) 0.822 (0.734–0.920)
Marital Status
Never Married 1 1
Married 1.099 (1.078–1.120) 0.938 (0.896–0.982)
Separated 0.744 (0.721–0.768) 0.835 (0.778–0.897)
Divorced or Widowed 0.911 (0.891–0.931) 0.813 (0.772–0.857)
Living Arrangement
Independent 1 1
Dependent 0.550 (0.541–0.560) 0.706 (0.670–0.745)
Homeless 0.527 (0.515–0.540) 0.731 (0.681–0.784)
Veteran Status 1.004 (0.962–1.048) 1.100 (0.988–1.224)
Years of Education
<8 Years 1 1
9–11 Years 1.031 (0.999–1.063) 1.185 (1.099–1.278)
12 Years 1.025 (0.996–1.056) 1.061 (0.989–1.138)
13–15 Years 0.723 (0.700–0.746) 0.956 (0.882–1.035)
16+ Years 1.081 (1.041–1.123) 0.905 (0.826–0.992)
Employment Status
Full-Time 1 1
Part-Time 0.981 (0.956–1.007) 0.974 (0.915–1.036)
Unemployed 0.696 (0.683–0.708) 0.868 (0.812–0.928)
Not in Labor Force 1.025 (1.006–1.044) 0.770 (0.717–0.827)
Primary Source of Income
Wages/Salary 1 1
Public Assistance 1.925 (1.872–1.980) 1.265 (1.175–1.361)
Retirement/Pension or Disability 1.898 (1.840–1.957) 1.241 (1.147–1.343)
Other 1.049 (1.024–1.075) 0.989 (0.923–1.059)
None 0.411 (0.402–0.420) 0.991 (0.928–1.059)
Health Insurer
Private 1 1
(Continued)
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treatment compared to White Americans. Compared to those who were never married, those
who were separated, divorced, or widowed showed higher odds of waiting over a week to enter
treatment. Those in a dependent living situation or homeless showed lower odds of waiting
over a week to enter treatment compared to those who reported living independently. No sta-
tistically significant difference was observed in the odds of waiting over a week to enter treat-
ment between veterans and non-veterans. Those working part-time showed higher odds of
waiting over a week to enter treatment vis-à-vis those working in full-time employment. More-
over, those reporting no primary source of income showed lower odds of waiting over a week
to enter treatment than those reporting a primary income from wages/salary. Those covered
by Medicaid showed lower odds of waiting over a week to enter treatment compared to those
who were insured privately.
Institutional characteristics. Admissions to all examined non-hospital settings were
associated with lower odds of waiting over a week to enter treatment. Compared those who
were individually referred for treatment (including self-referrals), those who were referred by
an alcohol/drug abuse care provider, other community referrer, or the criminal justice system
showed higher odds of waiting over a week to enter treatment. In addition, those reporting
alcohol or benzodiazepines at admission also showed higher odds of waiting over a week to
enter treatment.
Discussion
Our findings highlight several differences in the receipt of OAT and waiting time to enter
treatment on patient sociodemographic, institutional and behavioural characteristics.
Firstly, we note that only a minority of patients admitted for OUD receive OAT with some
Table 3. (Continued)
Characteristic Unadjusted Adjusted�
OR 95% CI AOR 95% CI
Medicaid 3.556 (3.423–3.694) 1.676 (1.579–1.779)
Medicare or Other 1.377 (1.312–1.445) 1.348 (1.242–1.464)
Uninsured 0.615 (0.589–0.641) 1.049 (0.986–1.116)
Service Setting at Time of Admission
Hospital 1 1
Short-Term 1.071 (0.893–1.284) 4.455 (1.076–18.45)
Long-Term 1.016 (0.845–1.220) 3.986 (0.960–16.56)
Ambulatory, Intensive Outpatient 1.830 (1.528–2.192) 5.420 (1.310–22.42)
Ambulatory, Non-Intensive Outpatient 13.24 (11.07–15.83) 37.69 (9.116–155.9)
Primary Source of Referral
Individual (including Self-Referral) 1 1
Alcohol/Drug Abuse Care Provider 0.323 (0.314–0.331) 0.437 (0.410–0.467)
Other Health Care Provider 0.261 (0.254–0.268) 0.512 (0.482–0.543)
Educational Institution 0.129 (0.0892–0.188) 0.114 (0.0438–0.294)
Employer 0.0717 (0.0584–0.0881) 0.101 (0.0636–0.159)
Other Community Referral 0.385 (0.377–0.393) 0.253 (0.241–0.266)
Court/Criminal Justice Referral/DUI 0.0558 (0.0544–0.0574) 0.0686 (0.0651–0.0724)
Alcohol or Benzodiazepines Reported at Admission 0.287 (0.282–0.292) 0.464 (0.445–0.484)
�Adjusted for year, state, age, sex, ethnicity, marital status, living arrangement, veteran status, years of education, employment status, primary source of income, health
insurer, census division, service setting at time of admission, primary source of referral, and alcohol/benzodiazepine report at admission.
https://doi.org/10.1371/journal.pone.0226349.t003
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Table 4. Logistic regression estimates for over one week spent waiting to enter treatment for opioid use disorder among admitted patients, 2014–17.
Characteristic Unadjusted Adjusted�
OR 95% CI AOR 95% CI
Age
18–20 1 1
21–24 0.949 (0.888–1.013) 1.047 (0.941–1.165)
25–29 0.886 (0.832–0.944) 1.119 (1.009–1.241)
30–34 0.821 (0.770–0.876) 1.077 (0.968–1.198)
35–39 0.825 (0.771–0.883) 1.080 (0.965–1.210)
40–44 0.684 (0.634–0.737) 0.966 (0.854–1.093)
45–49 0.622 (0.576–0.671) 1.069 (0.942–1.213)
50–54 0.516 (0.475–0.560) 0.954 (0.834–1.092)
55+ 0.483 (0.446–0.523) 0.889 (0.773–1.022)
Female 0.999 (0.974–1.024) 1.010 (0.968–1.055)
Ethnicity
White 1 1
Black or African American 0.574 (0.551–0.598) 0.886 (0.833–0.943)
Asian or Pacific Islander 0.821 (0.722–0.932) 0.924 (0.753–1.134)
Native American 1.115 (0.997–1.246) 0.977 (0.807–1.183)
Other 0.967 (0.921–1.015) 0.980 (0.861–1.114)
Marital Status
Never Married 1 1
Married 1.057 (1.015–1.101) 1.030 (0.968–1.096)
Separated 1.215 (1.145–1.290) 1.156 (1.058–1.264)
Divorced or Widowed 1.149 (1.101–1.200) 1.137 (1.063–1.216)
Living Arrangement
Independent 1 1
Dependent 1.119 (1.084–1.155) 0.933 (0.883–0.986)
Homeless 1.262 (1.212–1.315) 0.892 (0.823–0.967)
Veteran Status 1.038 (0.955–1.129) 0.910 (0.798–1.037)
Years of Education
<8 Years 1 1
9–11 Years 1.076 (1.004–1.152) 1.115 (1.003–1.238)
12 Years 1.051 (0.984–1.122) 1.069 (0.968–1.181)
13–15 Years 1.382 (1.290–1.482) 1.103 (0.991–1.227)
16+ Years
Employment Status
Full-Time 1 1
Part-Time 1.125 (1.065–1.188) 1.209 (1.114–1.313)
Unemployed 1.093 (1.052–1.135) 1.060 (0.970–1.158)
Not in Labor Force 0.864 (0.831–0.899) 1.019 (0.928–1.119)
Primary Source of Income
Wages/Salary 1 1
Public Assistance 0.680 (0.639–0.723) 0.956 (0.863–1.059)
Retirement/Pension or Disability 0.691 (0.647–0.737) 0.978 (0.876–1.093)
Other 0.684 (0.645–0.726) 0.966 (0.878–1.062)
None 1.207 (1.163–1.254) 0.894 (0.823–0.970)
Health Insurer
Private 1 1
(Continued)
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subpopulations exhibiting much lower receipt of OAT than others. For instance, only 18% of
those aged 18–20 received OAT compared to almost 60% of patients aged 55 and over who
received OAT. Similarly, while approximately three-quarters of admitted patients were treated
with no reported wait time, some subpopulations reported differentially higher rates of those
waiting for over a week to enter treatment, such as those aged 18–20, those who were privately
insured and those admitted to the hospital setting. Some subpopulations showed higher odds
of receipt of OAT, including all age groups older than the reference group of patients aged
18–20, Native Americans, patients whose primary source of income was public assistance or
retirement/pension or disability funds, those insured on Medicaid or Medicare, and those
admitted to non-hospital care settings. By contrast, some groups showed lower odds of receipt
of OAT, including those with a marital status other than the reference group who were never
married, those in a dependent living situation or homeless, and those patients for whom the
primary source of referral was anything other than an individual referral. With respect to
covariates associated with increased odds of waiting over a week to enter treatment, our analy-
sis highlighted several groups, including those who were separated, divorced, or widowed,
those working part-time, and those who were referred by alcohol/drug abuse care providers,
community referrers, or the criminal justice system.
Our analysis is necessarily limited by use of the TEDS-A dataset. Firstly, given the relative
complexity of reporting from the facility to the state to the Federal level, variations on report-
ing mechanisms by state may have downstream effects on the quality of data at the national
level [30]. In addition, information on days waiting to enter treatment are collected through
TEDS Supplementary Data which is voluntary [19]. As such, facilities with longer waiting
times may choose not to submit this information thereby contributing a level of reporting bias
Table 4. (Continued)
Characteristic Unadjusted Adjusted�
OR 95% CI AOR 95% CI
Medicaid 0.522 (0.491–0.555) 0.914 (0.846–0.987)
Medicare or Other 0.871 (0.803–0.945) 0.975 (0.881–1.080)
Uninsured 1.045 (0.982–1.112) 0.964 (0.894–1.039)
Service Setting at Time of Admission
Hospital 1 1
Short-Term 0.273 (0.216–0.344) 0.382 (0.284–0.514)
Long-Term 0.389 (0.308–0.491) 0.547 (0.405–0.740)
Ambulatory, Intensive Outpatient 0.180 (0.142–0.227) 0.221 (0.164–0.297)
Ambulatory, Non-Intensive Outpatient 0.133 (0.105–0.167) 0.243 (0.181–0.326)
Primary Source of Referral
Individual (including Self-Referral) 1 1
Alcohol/Drug Abuse Care Provider 1.885 (1.802–1.973) 1.322 (1.226–1.426)
Other Health Care Provider 1.536 (1.451–1.626) 1.024 (0.933–1.124)
Educational Institution 1.848 (1.060–3.221) 0.909 (0.317–2.609)
Employer 1.823 (1.332–2.495) 1.414 (0.904–2.210)
Other Community Referral 1.316 (1.260–1.374) 1.789 (1.668–1.918)
Court/Criminal Justice Referral/DUI 2.270 (2.204–2.338) 1.805 (1.716–1.899)
Alcohol or Benzodiazepines Reported at Admission 1.646 (1.599–1.695) 1.226 (1.171–1.283)
�Adjusted for year, state, age, sex, ethnicity, marital status, living arrangement, veteran status, years of education, employment status, primary source of income, health
insurer, census division, service setting at time of admission, primary source of referral, and alcohol/benzodiazepine report at admission.
https://doi.org/10.1371/journal.pone.0226349.t004
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to our analysis leading to the underestimation of actual waiting times to enter treatment.
Importantly, inferences regarding national trends and patterns are limited given that 7 states
did not report any patients in receipt of OAT and 13 states did not report time waiting to enter
treatment. Many of these states are critical to accurately assessing these outcomes respectively,
at a national level and so our inferences should be interpreted cautiously without their inclu-
sion. Additionally, given that our analyses are limited to only first-time admissions for the
treatment of OUD, we do not include subsequent admissions for the treatment of OUD fol-
lowing admissions for detoxification or prior admissions for treatment. We recognise that this
may distort our estimates of OAT for the treatment of OUD, given that an individual may be
admitted several times before receiving OAT. Moreover, TEDS-A does not include the use of
OATs in the primary care setting and, consequently, conclusions regarding the use of OATs in
primary care cannot be drawn from our analysis though data on the topic is available in estab-
lished literature [31–33]. Nevertheless, no other dataset exists at the national level which pro-
vides comparable data to TEDS-A. Consequently, despite the limitations presented here, our
study draws upon the largest extant dataset to provide information on OAT and time waiting
to enter treatment.
Addressing differences in treating individuals affected by OUD is a chief concern for pol-
icymakers and care providers. One systematic review of determinants of opioid-related mor-
tality in the United States and Canada has found opioid-related mortality trends tend to vary
considerably by sociodemographic differences, including ethnicity, gender, age, and socioeco-
nomic status, as we have highlighted here [34]. For many of these subpopulations, differences
in the treatment of OUD occurs concomitantly with differential treatment more generally,
exacerbating existing known disparities in healthcare provision based on factors such as race
[35]. Indeed, failure to treat OUD must be considered more widely. Perlman and Jordan, for
instance, highlight the complex inter-relationships among opioid misuse and overdose, hepati-
tis C, and HIV as a syndemic with disproportionately adverse results for individuals at height-
ened risk [36]. These concurrent conditions may further problematize the treatment of OUD
and, indeed, may contribute to a myriad of downstream metabolic comorbidities although
much remains unknown [37]. In addition, our findings regarding individuals referred by the
criminal justice system are consistent with the literature regarding the relatively low uptake of
pharmacotherapy for opioid use disorder among incarcerated individuals [38], a subgroup
which has exhibited a heightened risk of opioid overdose mortality following post-release [39].
As a result, OUD, taken in context of wider trends in population health, is increasingly an
urgent priority and differences in treatment must be addressed both in the near- and long-
term.
Our analysis highlights a number of areas for further scrutiny. Firstly, although OAT is
widely considered the standard of care for OUD, only a minority of admitted patients receive
it. Moreover, variations in who receives OAT and time to enter treatment based on sociode-
mographic and institutional characteristics highlight further areas for further study and poten-
tial intervention. In addition, further research is needed regarding personalised approaches to
characterising the inheritable factors which contribute towards heightened risk of OUD as
well as potential avenues for more effective treatment [40]. Nevertheless, given the limitations
of the TEDS-A dataset, we are unable to unravel the causal mechanisms which underlie these
differences. Stigma is commonly cited as a major factor which attenuates greater uptake of
OAT for the treatment of OUD but access remains strictly controlled and also contributes to
some patterns we have highlighted here [41]. Further attention is warranted to understand
how and why these differences exist and persist in order to formulate appropriate policy
responses.
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